Abstract: A method of treating a mammal with a tumor by decreasing intratumoral vessels associated with tumor or inhibiting formation of new intratumoral vessels includes injecting tumor with therapeutically effective amount of expression plasmid including polynucleotide coding for therapeutic peptide consisting of SEQ ID NO: 2 absent any operably linked coding sequence, wherein polynucleotide sequence is operably linked to promoter or expression control sequence, followed by application of electric pulses to site of injection in tumor or injecting muscle of mammal with therapeutically effective amount of expression plasmid including polynucleotide coding for therapeutic peptide consisting of SEQ ID NO: 2 absent any operably linked coding sequence, wherein polynucleotide sequence is operably linked to promoter or expression control sequence, followed by applying electric pulses to site of injection in muscle of mammal, whereby expression of SEQ ID NO: 2 decreases intratumoral vessels associated with tumor, or formation

Abstract: A method of inhibiting angiogenesis or invasion or formation of metastases in a mammal including administering a therapeutically effective amount of an active agent selected from the group consisting of a protein substance including all or part of a disintegrin domain of an adamalysin or a derivative thereof, a nucleic acid molecule including a polynucleotide sequence coding all or part of the disintegrin domain of an adamalysin or a derivative thereof to the mammal.

Abstract: The present invention relates to gene therapy for the treatment of tumors. The invention more particularly relates to introduction of a gene encoding an anti-angiogenic factor into cells of a tumor, for example with a defective adenovirus vector, to inhibit growth or metastasis, or both, of the tumor. In a specific embodiment, delivery of a defective adenovirus that expresses the amino terminal fragment of urokinase (ATF) inhibited growth and metastasis of tumors. These effects were correlated with a remarkable inhibition of neovascularization within, and at the immediate vicinity of, the injection site. Delivery of a defective adenovirus vector that expresses kringles 1 to 3 of angiostatin inhibited tumor growth and tumorigenicity, and induced apoptosis of tumor cells. The invention further provides viral vectors for use in the methods of the invention.

Abstract: A method of inhibiting angiogenesis or invasion or formation of metastases in a mammal including administering a therapeutically effective amount of an active agent selected from the group consisting of a protein substance including all or part of a disintegrin domain of an adamalysin or a derivative thereof, a nucleic acid molecule including a polynucleotide sequence coding all or part of the disintegrin domain of an adamalysin or a derivative thereof to the mammal.

Abstract: The present invention relates to gene therapy for the treatment of tumors. The invention more particularly relates to introduction of a gene encoding an anti-angiogenic factor into cells of a tumor, for example with a defective adenovirus vector, to inhibit growth or metastasis, or both, of the tumor. In a specific embodiment, delivery of a defective adenovirus that expresses the amino terminal fragment of urokinase (ATF) inhibited growth and metastasis of tumors. These effects were correlated with a remarkable inhibition of neovascularization within, and at the immediate vicinity of, the injection site. Delivery of a defective adenovirus vector that expresses kringles 1 to 3 of angiostatin inhibited tumor growth and tumorigenicity, and induced apoptosis of tumor cells. The invention further provides viral vectors for use in the methods of the invention.

Abstract: The peptides according to the invention are of the following general formula I:Z-Lys-Arg-Asp-X-Y (I)wherein:X is the residue of one of the 20 common aminoacids in the L-configuration,Y is hydroxyl or the C-terminal residue of one of the 20 common aminoacids in the L-configuration,Z is acetyl, hydrogen or the N-terminal residue of one of the 20 common aminoacids in the L-configuration, as the case may be N-acetylated, whereby it is understood that:when Y is the C-terminal residue of one of the 20 common aminoacids in the L-configuration, Z is acetyl or hydrogen andX can in all cases be different from Y and from Z.Application to the preparation of anti-thrombotic medicines.